Skip to main content
. Author manuscript; available in PMC: 2014 Jul 28.
Published in final edited form as: Urol Oncol. 2013 Mar 17;32(1):35.e15–35.e19. doi: 10.1016/j.urolonc.2013.01.009

Fig. 2.

Fig. 2

Recurrence-free survival based on pathology. (A) RFS based on stage. CIS—58% CR, 38% 1-RFS, and 23% 2-RFS. Ta—90% CR, 50% 1-RFS, and 50% 2-RFS. T1—67% CR, 60% 1-RFS, and 60% 2-RFS. (B) RFS based on grade. High grade—62% CR, 44% 1-RFS, and 33% 2-RFS. Low grade—100% CR, 63% 1-RFS, and 57% 2-RFS. (Color version of figure is available online.)